Literature DB >> 19148139

Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.

E Kostareli1, A Hadzidimitriou, N Stavroyianni, N Darzentas, A Athanasiadou, M Gounari, V Bikos, A Agathagelidis, T Touloumenidou, I Zorbas, A Kouvatsi, N Laoutaris, A Fassas, A Anagnostopoulos, C Belessi, K Stamatopoulos.   

Abstract

The chronic lymphocytic leukemia (CLL) immunoglobulin repertoire is uniquely characterized by the presence of stereotyped B-cell receptors (BCRs). A major BCR stereotype in CLL is shared by immunoglobulin G-switched cases utilizing the immunoglobulin heavy-chain variable 4-34 (IGHV4-34) gene. Increased titers of IGHV4-34 antibodies are detected in selective clinical conditions, including infection by B-cell lymphotropic viruses, particularly Epstein-Barr virus (EBV) and cytomegalovirus (CMV). In this context, we sought evidence for persistent activation by EBV and CMV in CLL cases expressing the IGHV4-34 gene. The study group included 93 CLL cases with an intentional bias for the IGHV4-34 gene. On the basis of real-time PCR results for CMV/EBV DNA, cases were assigned to three groups: (1) double-negative (59/93); (2) single-positive (CMV- or EBV-positive; 25/93); (3) double-positive (9/93). The double-negative group was characterized by heterogeneous IGHV gene repertoire. In contrast, a bias for the IGHV4-34 gene was observed in the single-positive group (9/25 cases; 36%). Remarkably, all nine double-positive cases utilized the IGHV4-34 gene; seven of nine cases expressed the major BCR stereotype as described above. In conclusion, our findings indicate that the interactions of CLL progenitor cells expressing distinctive IGHV4-34 BCRs with viral antigens/superantigens might facilitate clonal expansion and, eventually, leukemic transformation. The exact type, timing and location of these interactions remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148139     DOI: 10.1038/leu.2008.379

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  33 in total

1.  Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Mahmoud Mansouri; Meena Kanduri; Anders Isaksson; Hanna Göransson; Karin Ekström Smedby; Jesper Jurlander; Gunnar Juliusson; Fred Davi; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

2.  High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Nicola Cahill; Rebeqa Gunnarsson; Anders Isaksson; Mahmoud Mansouri; Hanna Göransson; Markus Rasmussen; Mattias Jansson; Fergus Ryan; Karin Karlsson; Hans-Olov Adami; Fred Davi; Jesper Jurlander; Gunnar Juliusson; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

4.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

5.  Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph.

Authors:  Delphine Casabonne; Oscar Reina; Yolanda Benavente; Nikolaus Becker; Marc Maynadié; Lenka Foretová; Pierluigi Cocco; Anna González-Neira; Alexandra Nieters; Paolo Boffetta; Jaap M Middeldorp; Silvia de Sanjose
Journal:  Haematologica       Date:  2010-11-03       Impact factor: 9.941

6.  An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.

Authors:  James C Romero-Masters; Makoto Ohashi; Reza Djavadian; Mark R Eichelberg; Mitchell Hayes; Nicholas A Zumwalde; Jillian A Bristol; Scott E Nelson; Shidong Ma; Erik A Ranheim; Jenny E Gumperz; Eric C Johannsen; Shannon C Kenney
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

7.  Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

Authors:  Stavroula Ntoufa; Anna Vardi; Nikos Papakonstantinou; Achilles Anagnostopoulos; Vassiliki Aleporou-Marinou; Chrysoula Belessi; Paolo Ghia; Federico Caligaris-Cappio; Marta Muzio; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

8.  An entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4.

Authors:  Lesley-Ann Sutton; Giorgos Papadopoulos; Anastasia Hadzidimitriou; Stavros Papadopoulos; Efterpi Kostareli; Richard Rosenquist; Dimitrios Tzovaras; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2015-04-02       Impact factor: 6.354

9.  Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.

Authors:  C Steininger; L Z Rassenti; K Vanura; K Eigenberger; U Jäger; T J Kipps; C Mannhalter; S Stilgenbauer; T Popow-Kraupp
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

10.  The molecular basis of familial chronic lymphocytic leukemia.

Authors:  Dalemari Crowther-Swanepoel; Richard S Houlston
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.